CD19 and acute myeloid leukemia: Furthermore, considering that the duration of remission induced by CD19 CAR-T cell therapy is short in the present study, allo-HSCT should be performed as soon as possible to eradicate the residual tumor cells, including CD19-negative subclones, and then reduce the risk of relapse and achieve long-term tumor remission in R/R t(8;21) AML (10, 22).